NCT00002243View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

DRUG

Calanolide A

Trial Locations (9)

10003

Beth Israel Med Ctr, New York

15213

Anderson Clinical Research / Inc, Pittsburgh

32960

Treasure Coast Infectious Disease Consultants, Vero Beach

37212

Vanderbilt Univ Med Ctr, Nashville

60612

Cook County Hosp, Chicago

212011192

Univ of Maryland Institute of Human Virology, Baltimore

331813405

South Florida Bioavailability Clinic, Miami

775550835

Univ of Texas / Med Branch at Galveston, Galveston

02118

Boston Med Ctr / Clinical Research Office, Boston

All Listed Sponsors

lead

Sarawak MediChem Pharmaceuticals

INDUSTRY

NCT00002243 - A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment | Biotech Hunter | Biotech Hunter